Aegerion Pharmaceuticals Receives Consensus Rating of “Hold” from Brokerages (NASDAQ:AEGR)
Aegerion Pharmaceuticals (NASDAQ:AEGR) has received a consensus rating of “Hold” from the eleven ratings firms that are currently covering the company, Analyst Ratings Network reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $63.25.
In other Aegerion Pharmaceuticals news, CEO Marc D. Beer acquired 10,000 shares of the stock in a transaction dated Thursday, July 31st. The shares were purchased at an average cost of $33.65 per share, for a total transaction of $336,500.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
A number of analysts have recently weighed in on AEGR shares. Analysts at Zacks reiterated a “neutral” rating on shares of Aegerion Pharmaceuticals in a research note on Wednesday, July 16th. They now have a $29.00 price target on the stock. Analysts at Goldman Sachs initiated coverage on shares of Aegerion Pharmaceuticals in a research note on Tuesday, May 27th. They set a “sell” rating and a $27.00 price target on the stock.
Aegerion Pharmaceuticals (NASDAQ:AEGR) opened at 31.56 on Tuesday. Aegerion Pharmaceuticals has a one year low of $26.25 and a one year high of $101.00. The stock’s 50-day moving average is $30.9 and its 200-day moving average is $42.67. The company’s market cap is $930.8 million.
Aegerion Pharmaceuticals (NASDAQ:AEGR) last announced its earnings results on Tuesday, July 29th. The company reported ($0.33) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.41) by $0.08. The company had revenue of $36.00 million for the quarter, compared to the consensus estimate of $35.40 million. During the same quarter in the previous year, the company posted ($0.66) earnings per share. The company’s revenue for the quarter was up 453.8% on a year-over-year basis. On average, analysts predict that Aegerion Pharmaceuticals will post $-0.87 earnings per share for the current fiscal year.
Aegerion Pharmaceuticals, Inc (NASDAQ:AEGR) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat lipid disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.